Growth hormone (GH) deficiency (GHD) in children is defined as impaired production of GH
by the pituitary gland that results in growth failure. This disease might be congenital or …

Abstract This International Consensus Guideline was developed by experts in the field of
small for gestational age (SGA) of 10 pediatric endocrine societies worldwide. A consensus …

Context Growth hormone (GH) treatment has a generally good safety profile; however,
concerns about increased mortality risk in adulthood have been raised. Objective This work …

Tackling the mechanisms underlying ageing is desirable to help to extend the duration and
improve the quality of life. Life extension has been achieved in animal models by …

Background: Daily recombinant human growth hormone (rhGH) is approved and marketed
worldwide to treat children and adults with GH deficiency and other conditions. Efficacy of …

As we continue to understand more about the complex mechanism of growth, a plethora of
novel therapies have recently been developed that aim to address barriers and optimize …

Growth hormone (GH) therapy dates back to 1958 and, though has shown an excellent
safety profile in the short-term, has never ceased to raise concern about potential long-term …

Growth hormone treatment was introduced in the 1950s to address growth disturbances and
metabolic abnormalities. Hundreds of thousands of children have been treated, with gradual …

Noonan syndrome (NS) is a disorder characterized by a typical facial gestalt, congenital
heart defects, variable cognitive deficits, skeletal defects, and short stature. NS is caused by …

The use of recombinant human growth hormone (rhGH) in children and adolescents has
expanded since its initial approval to treat patients with severe GH deficiency (GHD) in 1985 …